{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:26:19Z","timestamp":1790263579964,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacists play a key role in ensuring the safe use of injectable antineoplastics, which are considered as high-alert medications. Pharmaceutical analysis of injectable antineoplastic prescriptions aims to detect and prevent drug related problems by proposing pharmacist interventions (PI). The impact of this activity for patients, healthcare facilities and other health professionals is not completely known. This study aimed at describing the clinical, economic, and organizational impacts of PIs performed by pharmacists in a chemotherapy preparation unit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective 10-week study was conducted on PIs involving injectable antineoplastic prescriptions. Each PI was assessed by one of the four multidisciplinary expert committees using a multidimensional tool with three independent dimensions: clinical, economic and organizational. An ancillary quantitative evaluation of drug cost savings was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 185 patients were included (mean age: 63.5\u2009\u00b1\u200913.7\u2009years; 54.1% were male) and 237 PIs concerning 10.1% prescriptions were recorded. Twenty one PIs (8.9%) had major clinical impact (ie: prevented hospitalization or permanent disability), 49 PIs (20.7%) had moderate clinical impact (ie: prevented harm that would have required further monitoring\/treatment), 62 PIs (26.2%) had minor clinical impact, 95 PIs (40.0%) had no clinical impact, and 9 PIs (3.8%) had a negative clinical impact. For one PI (0.4%) the clinical impact was not determined due to insufficient information. Regarding organizational impact, 67.5% PIs had a positive impact on patient management from the healthcare providers\u2019 perspective. A positive economic impact was observed for 105 PIs (44.3%), leading to a saving in direct drug costs of 15,096 \u20ac; 38 PIs (16.0%) had a negative economic impact, increasing the direct drug cost by 11,878 \u20ac. Overall cost saving was 3218\u20ac.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PIs are associated with positive clinical, economic and organizational impacts. This study confirms the benefit of pharmacist analysis of injectable antineoplastic prescriptions for patient safety with an overall benefit to the healthcare system.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-020-4963-7","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:02:43Z","timestamp":1581526963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical, economic and organizational impact of pharmacist interventions on injectable antineoplastic prescriptions: a prospective observational study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-9160","authenticated-orcid":false,"given":"C\u00e9line","family":"Zecchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi-Ha","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Chanoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Laramas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Lemoigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Allenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Federspiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Bedouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"4963_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-002-0501-2","volume":"58","author":"L Juntti-Patinen","year":"2002","unstructured":"Juntti-Patinen L, Neuvonen PJ. Drug-related deaths in a university central hospital. Eur J Clin Pharmacol. 2002;58:479\u201382.","journal-title":"Eur J Clin Pharmacol"},{"key":"4963_CR2","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/ajhp\/58.19.1835","volume":"58","author":"J Phillips","year":"2001","unstructured":"Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health-Syst Pharm. 2001;58:1835\u201341.","journal-title":"Am J Health-Syst Pharm"},{"key":"4963_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/00039899709602893","volume":"52","author":"PJ Sessink","year":"1997","unstructured":"Sessink PJ, Wittenhorst BC, Anzion RB, Bos RP. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997;52:240\u20134.","journal-title":"Arch Environ Health"},{"key":"4963_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/107815529600200308","volume":"2","author":"M Favier","year":"1996","unstructured":"Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator. J Oncol Pharm Pract. 1996;2:182\u20135.","journal-title":"J Oncol Pharm Pract"},{"key":"4963_CR5","unstructured":"Pharmaceutical Care Network Europe Foundation PCNE Classification for drug-related problems V8.02. 2018. Website https:\/\/www.pcne.org Accessed 9 sept 2018."},{"key":"4963_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2125.2003.02029.x","volume":"57","author":"MJ Dooley","year":"2004","unstructured":"Dooley MJ, Allen KM, Doecke CJ, Galbraith KJ, Taylor GR, Bright J, et al. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol. 2004;57:513\u201321.","journal-title":"Br J Clin Pharmacol"},{"key":"4963_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11096-006-9027-5","volume":"28","author":"B Allenet","year":"2006","unstructured":"Allenet B, Bedouch P, Rose F-X, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument for the documentation of clinical pharmacists\u2019 interventions. Pharm World Sci. 2006;28:181\u20138.","journal-title":"Pharm World Sci"},{"key":"4963_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2478\/v10019-010-0040-x","volume":"44","author":"L Knez","year":"2010","unstructured":"Knez L, Laaksonen R, Duggan C. Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol. 2010;44:249\u201356.","journal-title":"Radiol Oncol"},{"key":"4963_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1078155213519836","volume":"21","author":"C Chew","year":"2015","unstructured":"Chew C, Chiang J, Yeoh TT. Impact of outpatient interventions made at an ambulatory cancer Centre oncology pharmacy in Singapore. J Oncol Pharm Pract. 2015;21:93\u2013101.","journal-title":"J Oncol Pharm Pract"},{"key":"4963_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1590\/S1679-45082016AO3667","volume":"14","author":"TF Farias","year":"2016","unstructured":"Farias TF. Aguiar K da S, Rotta I, Belletti KM da S, Carlotto J. Implementing a clinical pharmacy service in hematology. Einstein. 2016;14:384\u201390.","journal-title":"Einstein"},{"key":"4963_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/jcpt.12562","volume":"42","author":"LRP Colombo","year":"2017","unstructured":"Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J Clin Pharm Ther. 2017;42:414\u201324.","journal-title":"J Clin Pharm Ther"},{"key":"4963_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1472-6963-14-57","volume":"14","author":"G Fasola","year":"2014","unstructured":"Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57.","journal-title":"BMC Health Serv Res"},{"key":"4963_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","volume":"277","author":"DW Bates","year":"1997","unstructured":"Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA. 1997;277:307\u201311.","journal-title":"JAMA."},{"key":"4963_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1472-6963-14-177","volume":"14","author":"J Gallagher","year":"2014","unstructured":"Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14:177.","journal-title":"BMC Health Serv Res"},{"key":"4963_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/ejhpharm-2016-001093","volume":"25","author":"B Claus","year":"2018","unstructured":"Claus B, Pourcq KD, Clottens N, Kruse V, Gemmel P, Vandenbroucke J. The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital. Eur J Hosp Pharm Sci Pract. 2018;25:334\u20136.","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"4963_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1078155217736376","volume":"25","author":"CE O\u2019Leary","year":"2019","unstructured":"O\u2019Leary CE, Collins A, Henman MC, King F. Introduction of a dose-banding system for parenteral chemotherapy on a haematology-oncology day ward. J Oncol Pharm Pract. 2019;25:351\u201361.","journal-title":"J Oncol Pharm Pract"},{"key":"4963_CR17","unstructured":"Vo T.-H. Evaluation of the potential impact of pharmacist interventions: development and validation of the CLEO multidimensional tool. Pharmaceutical sciences. Universit\u00e9 Grenoble Alpes. 2015. https:\/\/tel.archives-ouvertes.fr\/tel-01315619\/document Accessed 9 sept 2018."},{"key":"4963_CR18","doi-asserted-by":"publisher","first-page":"e9865","DOI":"10.1097\/MD.0000000000009865","volume":"97","author":"C Mongaret","year":"2018","unstructured":"Mongaret C, Quillet P, Vo TH, Aubert L, Fourgeaud M, Michelet-Huot E, et al. Predictive factors for clinically significant pharmacist interventions at hospital admission. Medicine (Baltimore). 2018;97:e9865.","journal-title":"Medicine (Baltimore)"},{"key":"4963_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11096-018-0755-0","volume":"41","author":"D Stampfli","year":"2019","unstructured":"Stampfli D, Baumgartner P, Boeni F, Bedouch P, Lampert ML, Hersberger KE. Translation and validation of a tool to assess the impact of clinical pharmacists\u2019 interventions. Int J Clin Pharm. 2019;41:56\u201364.","journal-title":"Int J Clin Pharm"},{"key":"4963_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ijmedinf.2010.07.003","volume":"79","author":"V Nerich","year":"2010","unstructured":"Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, et al. Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. Int J Med Inf. 2010;79:699\u2013706.","journal-title":"Int J Med Inf"},{"key":"4963_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s11096-016-0339-9","volume":"38","author":"J-M Han","year":"2016","unstructured":"Han J-M, Ah Y-M, Suh SY, Jung S-H, Hahn HJ, Im S-A, et al. Clinical and economic impact of pharmacists\u2019 intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38:1124\u20133.","journal-title":"Int J Clin Pharm"},{"key":"4963_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jcpt.12242","volume":"40","author":"N Vantard","year":"2015","unstructured":"Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat M-G, et al. EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther. 2015;40:196\u2013203.","journal-title":"J Clin Pharm Ther"},{"key":"4963_CR23","first-page":"33","volume":"25","author":"L Grangeasse","year":"2006","unstructured":"Grangeasse L, Juste M, Rose F-X, Roubille R, Chaigneau L, Medjoub M, Larosa F, Bracco-Nolin CH, et al. Computerized and protocolized prescription of chemotherapy, residual iatrogenic risk and pharmaceutical interventions. J Pharm Clin. 2006;25:33\u20138.","journal-title":"J Pharm Clin"},{"key":"4963_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11096-005-6034-x","volume":"27","author":"C Slama","year":"2005","unstructured":"Slama C, Jerome J, Jacquot C, Bonan B. Prescription errors with cytotoxic drugs and the inadequacy of existing classifications. Pharm World Sci PWS. 2005;27:339\u201343. 3.","journal-title":"Pharm World Sci PWS"},{"key":"4963_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1345\/aph.1L045","volume":"42","author":"P Bedouch","year":"2008","unstructured":"Bedouch P, Charpiat B, Conort O, Rose F-X, Escofier L, Juste M, et al. Assessment of clinical pharmacists\u2019 interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008;42:1095\u2013103.","journal-title":"Ann Pharmacother"},{"key":"4963_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/1471-2407-11-478","volume":"11","author":"F Ranchon","year":"2011","unstructured":"Ranchon F, Salles G, Sp\u00e4th H-M, Schwiertz V, Vantard N, Parat S, et al. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011;11:478.","journal-title":"BMC Cancer"},{"key":"4963_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1078155212447974","volume":"19","author":"V Nerich","year":"2013","unstructured":"Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich P-S, et al. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs. J Oncol Pharm. 2013;19:8\u201317.","journal-title":"J Oncol Pharm"},{"key":"4963_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/106002808802200318","volume":"22","author":"HT Hatoum","year":"1988","unstructured":"Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988;22:252\u20139.","journal-title":"Drug Intell Clin Pharm"},{"key":"4963_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ajhp\/58.9.784","volume":"58","author":"TW Nesbit","year":"2001","unstructured":"Nesbit TW, Shermock KM, Bobek MB, Capozzi DL, Flores PA, Leonard MC, et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health-Syst Pharm. 2001;58:784\u201390.","journal-title":"Am J Health-Syst Pharm."},{"key":"4963_CR30","first-page":"549","volume":"490","author":"F-X Rose","year":"2009","unstructured":"Rose F-X, Escofier L, Conort O, Charpiat B, Bedouch P, Allenet B, Roubille R, Juste M. Multicentric study of the economic impact of pharmaceutical interventions. Gest Hosp. 2009;490:549\u201354.","journal-title":"Gest Hosp"},{"key":"4963_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/amiajnl-2011-000205","volume":"18","author":"KC Nanji","year":"2011","unstructured":"Nanji KC, Rothschild JM, Salzberg C, Keohane CA, Zigmont K, Devita J, et al. Errors associated with outpatient computerized prescribing systems. J Am Med Inform Assoc JAMIA. 2011;18:767\u201373.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"4963_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1365-2753.2011.01704.x","volume":"18","author":"P Bedouch","year":"2012","unstructured":"Bedouch P, Tessier A, Baudrant M, Labarere J, Foroni L, Calop J, et al. Computerized physician order entry system combined with on-ward pharmacist: analysis of pharmacists\u2019 interventions. J Eval Clin Pract. 2012;18:911\u20138.","journal-title":"J Eval Clin Pract"},{"key":"4963_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/1472-6963-13-522","volume":"13","author":"M Aita","year":"2013","unstructured":"Aita M, Belvedere O, De Carlo E, Deroma L, De Pauli F, Gurrieri L, et al. Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems. BMC Health Serv Res. 2013;13:522.","journal-title":"BMC Health Serv Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-4963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-020-4963-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-4963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:42:43Z","timestamp":1613036563000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-020-4963-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4963"],"URL":"https:\/\/doi.org\/10.1186\/s12913-020-4963-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study ethics approval was obtained from CECIC Rh\u00f4ne-Alpes-Auvergne, Clermont-Ferrand (IRB 5891). The CECIC considering the recommended nature of the control of the prescription of high-alert medications by a hospital pharmacist and the usual character of this practice, did not raise any ethical problem with the publication of this work and judged unnecessary the request of written or verbal consent. The CECIC has allowed accessing and using the data and records described in the study. This decision was made after reviewing our project according to the French Law on Research Involving the Human Person and the Declaration of Helsinki of the World Medical Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}